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DIAGNOSTIC ASSAY FOR LATE-ONSET 
ALZHEMERS DISEASE 
The present application claims the priority of co-pending 
U.S. Provisional Patent Application Ser. No. 60/076,887, 
filed Mar. 5, 1998, the entire disclosure of which is incor 
porated herein by reference without disclaimer. 
The government may own rights in the present invention 
pursuant to grant number RO1 MH43353 from the National 
Institutes of Health and grant number 003658-361 from the 
Advanced Technology Program, State of Texas. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the fields of 
pathology and diagnostics. More particularly, it concerns the 
early diagnosis of late-onset sporadic Alzheimer's Disease 
(AD). More specifically, the invention relates to detecting 
changes in the level of mitochondrial cytochrome oxidase 
for diagnosing and monitoring AD. 
2. Description of Related Art 
Alzheimer's Disease (AD) is characterized by initial 
memory loSS, followed by progressive loSS of neurons 
leading to dementia and loSS of all nervous functions, and 
eventually death. AD is now the fourth-largest killer of 
adults 65 and older, and this disease impacts one of every 
three families in the United States (Gonzalez-Lima and 
Gonzalez-Lima, 1987), and affects over 13 million people 
World-wide. AS the population trends lead to an increase in 
the number of older people, this figure will only increase. 
AD may be categorized in one of two forms; familial AD 
or sporadic AD Familial AD accounts for only about 5% to 
10% of all Alzheimer's cases and has an unusually early 
onset, generally before the age of fifty. Familial AD is 
inherited and follows conventional patterns of Mendelian 
inheritance. This form of AD has been linked to nuclear 
chromosomal abnormalities. In contrast, the Second form of 
AD, Sporadic AD, is a late-onset disease which is not 
inherited or caused by nuclear chromosomal abnormalities. 
This late-onset form of the disease is the more common type 
of AD and is believed to account for approximately 90 to 
95% of all Alzheimer's cases. The cause of sporadic AD is 
not known. 
Mitochondrial DNA defects are thought to be involved in 
a number of degenerative diseases, including Leber's 
hereditary optic neuropathy and myoclonic epilepsy lactic 
acidosis and stroke (MELAS). Such defects also are thought 
to involved in the “sporadic” (non-Mendelian) occurrence of 
neurodegenerative diseaseS Such as Parkinson's and AD. 
Further, considering that the mitochondrion is the site of the 
electron transport pathway, it is not Surprising that aberrant 
electron function has been described in both Parkinson's 
disease and AD. Cytochrome oxidase (CO, also known as 
ferrocytochrome c:oxygen oxidoreductase, cytochrome aa3, 
EC 1.9.3.1) is a key component of the mitochondrial elec 
tron transport chain, where it is responsible for the activation 
of oxygen for aerobic energy metabolism in all eukaryotic 
cells. CO is the terminal rate-limiting enzyme for cellular 
respiration. Since the brain relies almost exclusively on the 
aerobic metabolism of glucose for its energy, CO function is 
essential for normal brain function. 
In recent years it has been reported that defects in cyto 
chrome oxidase, may be involved in AD. Parker et al. (1990) 
showed that patients with AD have reduced cytochrome 
oxidase activity. Further, it has also been shown that when 











cytochrome oxidase, the rats suffer from a form of behavior 
dysfunction characterized by impaired memory and learning 
(Bennett et al., 1992). These rats mimic the effect of AD in 
humans. In addition, the Sodium azide-treated rats failed to 
display long-term potentiation, demonstrating loSS of neu 
ronal plasticity. Therefore, a chronic defect in CO activity in 
AD leads to oxidative damage to mitochondrial DNA and 
preferential cell death in the brain (Mecocci et. al., 1994). 
The diagnosis of AD is by clinical observation and 
definitive diagnosis is only accomplished by pathological 
examination at autopsy. There have been many attempts to 
diagnose AD by identifying differences in biological mark 
erS Such as protease nexin II and apolipoprotein E alleles, as 
well as monitoring cathepsin D in the patient's cerebrospinal 
fluid (U.S. Pat. No. 5,686,269), monitoring amyloid precur 
sor protein (U.S. Pat. No. 5,705.401), and monitoring con 
centration of neuronal membrane phospholipids and phos 
pholipid metabolites (U.S. Pat. No. 5,545,566). However, 
these approaches generally have a low rate of Success or 
involve invasive techniques that are at best uncomfortable 
and often unreliable. 
Additionally, measurement of increased levels of neu 
ronal thread protein in cerebrospinal fluid of Alzheimer's 
patients has been proposed as a diagnostic test (de la Monte 
et al., 1992). Recently, this test has been available commer 
cially as AD7CTM from NYMOX. It involves a lumbar 
puncture performed by a physician to obtain the cerebroSpi 
nal fluid. But AD7CTM has the disadvantage that it cannot be 
used as an early diagnostic test effectively because it relayS 
on the increase in a protein resulting from neuronal degen 
eration. Therefore, Significantly elevated levels of neuronal 
thread protein in cerebroSpinal fluid can only be detected 
reliably after considerable irreversible neuronal death has 
occurred. 
Because AD is progressive in nature, the efficiency of a 
cure could critically depend upon early detection. 
Additionally, the value of any new therapy could be better 
assessed if a rapid, Safe and effective diagnostic procedure 
were available to monitor the progreSS of AD in patients 
following treatment. Therefore, there is a distinct need for a 
reliable, non-invasive, diagnostic laboratory test of AD So 
that this debilitating disorder may be detected at its earliest 
Stages for efficient and effective intervention and treatment. 
The present invention is designed to address these needs. 
SUMMARY OF THE INVENTION 
In order to overcome deficiencies in the art, the present 
invention provides a quantitative assay for early diagnosis of 
late-onset sporadic Alzheimer's Disease (AD) in living 
individuals using peripheral tissue biopsy. The assay also 
may be used for postmortem diagnosis. 
Thus, the present invention provides a method of diag 
nosing late-onset Sporadic AD comprising the Steps of 
obtaining a Sample from a human Subject; assessing cyto 
chrome oxidase activity in nucleated cells of the Sample, and 
comparing the cytochrome oxidase activity in nucleated 
cells of the Sample with the cytochrome oxidase activity of 
a Standard, wherein a decrease in cytochrome oxidase activ 
ity in nucleated cells of the Sample, with respect to the 
Standard, indicates that the Subject has AD. 
In preferred embodiments, the Standard is cytochrome 
oxidase activity of like cells from an individual not afflicted 
with AD. In other preferred embodiments, the method 
further comprises assessing cytochrome oxidase activity 
from the like cells. In particularly preferred embodiments, 
the Sample is a Superficial tissue biopsy. In more defined 
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embodiments, the biopsy is from a tissue Selected from the 
group consisting of muscle, dermis, epidermis, bone 
marrow, peripheral ganglion or nerve. In certain preferred 
embodiments, the Sample may be frozen and Sectioned. 
In particular aspects of the present invention, the assess 
ing comprises providing diaminobenzidine (DAB) to cells of 
the Sample and measuring oxidation of DAB to an indamine 
polymer. It is contemplated that measuring oxidation of 
DAB to an indamine polymer, when calibrated with Spec 
trophotometry provides quantitative cytochemistry. 
In particular embodiments, the cytochrome oxidase activ 
ity is quantified. In defined embodiments, the diagnostic 
cytochrome oxidase activity level of cells of the Sample is 
Significantly lower than the mean cytochrome oxidase activ 
ity level of the like cells. The term “significantly lower” as 
used herein is a cytochrome oxidase activity in the Sample 
that is lower than the cytochrome oxidase in like cells. In 
preferred embodiments, the cytochrome oxidase activity is 
10% or more below 15% or more below; 20% or more 
below; 25% or more below; 30% or more below; 35% or 
more below; 40% or more below; 45% or more below; 50% 
or more below; 55% or more below; 60% or more below; 
65% or more below; 70% or more below: 75% or more 
below; 80% or more below; 85% or more below or 90% or 
more below the mean cytochrome oxidase activity level of 
the like cells. 
Also contemplated by the present invention is a method 
for monitoring a treatment for late-onset sporadic AD com 
prising the Steps of obtaining a Sample from a human Subject 
following a treatment thereof, assessing cytochrome oxidase 
activity in nucleated cells of the Sample, and comparing the 
cytochrome oxidase activity in nucleated cells of the Sample 
with a Standard; wherein an increase in cytochrome oxidase 
activity in nucleated cells of the Sample, with respect to the 
Standard, indicates that the treatment is effective. In particu 
lar embodiments, the Standard is cytochrome oxidase activ 
ity of like cells from the subject prior to the treatment. In 
more preferred embodiments, the Standard is cytochrome 
oxidase activity of like cells from an individual not afflicted 
with AD. In other embodiments, the Sample is a Superficial 
tissue biopsy. 
In certain aspects of the invention, it is contemplated that 
the assessing comprises providing diaminobenzidine (DAB) 
to cells of the Sample and measuring oxidation of DAB to an 
indamine polymer. In more defined embodiments, measur 
ing oxidation of DAB to an indamine polymer comprises 
quantitative cytochemistry when calibrated with Spectropho 
tometry. In preferred embodiments, the Sample may be 
frozen and Sectioned. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the Specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, Since various changes and modifi 
cations within the Spirit and Scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present Specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of Specific 












FIG. 1A, FIG. 1B, and FIG. 1C. The macroscopic inferior 
colliculus. (Scanned image) FIG. 1A: general appearance of 
the cytochrome oxidase (CO) stained human inferior colli 
culus (IC). It appears as a dark, ovoid structure oriented 
diagonally along the dorsal aspect of a transverse Section 
through the midbrain. At most levels, it is clearly outlined by 
a ring of white matter: the incoming projections of the lateral 
lemniscus border the IC ventromedially and ventrolaterally, 
the commissure of the IC is present dorsomedially in rostral 
Sections, and the brachium of the IC extends out along the 
dorsolateral Surface. FIG. 1B: (Scanned images) the divi 
Sions with a Nissl stain. The IC can be Subdivided into three 
nuclei: (1) Central nucleus (ICC): this nucleus is the largest 
of the three and contains the main projection fields of the 
lateral lemniscus. It makes up the entire Ventromedial aspect 
of the IC, as outlined by the white matter of the lateral 
lemniscus. It is bordered dorsally and laterally by the other 
two nuclei. The ICC showed high metabolic activity 
(183.40+18.77 units). (2) Dorsal nucleus (ICD): this nucleus 
lies most dorsomedial just lateral to and making up portions 
of the commissure of the IC, This region showed high CO 
metabolic activity (184.98+45.08) which seems to corre 
spond to its greater packing density of active neuropil. (3) 
External nucleus (ICE): the lateral border of the ICC is 
formed by the external nucleus. This nucleus can be viewed 
as a lighter band of gray matter extending along the lateral 
side of the ICC from ventro- to dorsolateral in a transverse 
Section, bordered laterally by the lemniscus and brachium. 
This nucleus contained the lowest CO metabolic activity 
units (56.46+15.94). C: the distribution of large cells. The 
topographic distribution of CO deficits adjacent to the 
location of larger neurons in the ICC Suggests hearing loSS 
in AD involves both high and low tonotopic frequencies, 
CG, central gray. Scale bar equal for A, B, and C. Top is 
dorsal and right Side is lateral. 
FIG. 2A and FIG.2B. (Scanned images) FIG. 2A a large 
cell of the ICC, stained for CO. FIG. 2B the same cell 
outlined for measurement as listed in the text. Averaged CO 
measurements are shown as borders, peak measurements are 
shown as boxes approximating the size of the Sampled peak 
area. N, nucleus of cell. Scale bar equal for top and bottom 
figures. 
FIG. 3A, FIG. 3B and FIG. 3C. Cell body frequency 
histograms by Soma diameter in each of the three nuclei of 
the non-AD control group: ICC (FIG. 3A), ICD (FIG. 3B), 
and ICE (FIG. 3C). Note the bimodal distribution of cell 
bodies in the ICC; the control and AD groups were subdi 
vided at the mean of the control ICC Soma diameters, 12.1 
plm. 
FIG. 4A and FIG. 4B. Comparison between the morpho 
metric measures of areas (FIG. 4A), perimeters and diam 
eters (FIG. 4B) of the three nuclei of the IC within the 
non-AD control group. The ICC measures were significantly 
larger than both the ICD and ICE in all morphometric 
measures (p<0.05). 
FIG. 5. Comparison between the CO activity measures of 
the three nuclei of the IC within the non-AD control group. 
The ICC and ICD differed significantly from the ICE in 
overall average activity; the ICC alone Significantly differed 
from the ICE in the perikaryon average and peak measures 
(p<0.05). 
FIG. 6. Comparison of the larger than average cells of the 
ICC between AD and control. The controls showed signifi 
cantly more CO activity in the Overall average and neuropil 
peaks measures (p<0.05). This may reflect the heightened 
Vulnerability to AD of the larger projection neurons. 
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FIG. 7. Schematic of the model of the diaminobenzidine 
(DAB) cytochemical reaction adapted from Wong-Riley 
(1989) and Seligman et al. (1968). The staining in the 
cytochemical reaction is produced when DAB is oxidized to 
an indamine polymer (OXID DAB). Since continuous reoxi 
dation of Cyt C by CO is required for the accumulation of 
the visible OXID DAB, this reaction serves to visualize CO 
activity. 
FIG. 8A, FIG. 8B, FIG. 8C, FIG. 8D, FIG. 8E, FIG. 8F, 
FIG. 8G and FIG. 8H. Scanned images of peripheral and 
brain tissues from rats and humans stained with the CO 
technique of the present invention. Lower and higher mag 
nifications are shown in the left and right columns, respec 
tively. FIG. 8A and FIG. 8B show rat brain regions mea 
Sured. FIG. 8C and FIG. 8D show skeletal muscle, with 
clearly delineated red fibers (rich in mitochondrial enzymes) 
and white fibers (poor in mitochondrial enzymes). FIG. 8E 
and FIG. 8F show thin skin with cells in epidermis, dermis 
and smooth muscle fibers. FIG.8G and FIG.8H show higher 
magnifications of human nervous tissue from the midbrain, 
with well stained neuronal cell body characteristic of control 
subjects, from the study by Gonzalez-Lima et al. (1997). 
FIG. 9. Calibration curve showing the linear relationship 
between CO activity and optical density in the cytochemical 
tissue Standards. Activity units were measured spectropho 
tometrically and are expressed as limol/min/g tissue wet 
weight. Optical density of both brain and peripheral tissue 
Standards was measured with an imaging System calibrated 
with an optical density step tablet. Standard error bars of 
mean measures are shown, but in most cases are Smaller than 
the size of the symbols. 
FIG. 10. Effect of cytochemical incubation time on optical 
density of 40 um brain Sections. The increase in optical 
density was linear with respect to increasing time in the 37 
C. incubation medium. Standard error bars of mean mea 
Sures are shown, but in most cases are Smaller than the size 
of the symbols. 
FIG. 11. Effect of section thickness on optical density of 
Standard brain homogenate Sections incubated for 60 min at 
37 C. The increasing optical density was linear with respect 
to increased Section thickness of the paste Standards. Stan 
dard error bars of mean optical density are shown, but in 
most cases are Smaller than the Size of the Symbols. 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
Alzheimer's Disease is a debilitating neurodegenerative 
disease that is characterized by initial memory loSS, fol 
lowed by progressive loSS of neurons leading to dementia 
and loSS of all nervous functions, and eventually death. 
Sporadic late-onset AD accounts for 90%–95% of the total 
incidences of AD. Effectively, this disease can Strike any 
individual over age 65, with little or no warning. Early 
diagnosis of this condition is imperative for halting the 
nervous tissue damage and ameliorating this debilitating 
condition. An indicator of the Success of therapy is also 
necessary So that it can be determined whether a particular 
treatment regimen should be continued or abandoned. 
It has been shown that cytochrome oxidase (CO) defi 
ciency exists in the mitochondria of patients with AD 
(Parker et al., 1990). Subsequently, it has been shown that 
changes in cytochrome oxidase activity are indicative of 
AD. To date, the measurement of CO activity has required 
the use of neuronal tissue post-mortem, plateletpheresis and 
blood CO measurements. The diagnostic use of the assay 











plateletpheresis-based technique. This technique is not 
applicable to other peripheral tissues because it requires 
assays that were specifically developed for platelets, and 
which do not allow reliable measures of CO activity in other 
tissues. Simpler, more routine biochemical procedures for 
measuring CO activity in blood are too insensitive to detect 
the changes seen in AD patients (Van Zuylen et. al., 1992). 
Thus, the extent to which peripheral tissues provide reliable 
information is unknown. Moreover, because reliable diag 
nosis of AD requires the use of neuronal tissue, it has not 
been possible, thus far, to diagnose AD using peripheral 
tissues. 
The present invention, for the first time, provides a 
Simple, Sensitive and reliable way of detecting AD in a living 
Subject. The inventor has developed an assay that has the 
Sensitivity to be a useful assay when employed in peripheral 
tissue, thereby ameliorating the need for neuronal or Spinal 
cord tissue. Thus, in a preferred embodiment, the present 
invention provides an assay that can be used in peripheral 
tissues other than blood to provide a measure of the cellular 
CO activity. This assay can accurately quantify the CO 
activity of an individual using cytochemical procedures and 
automated image analysis. 
1. Involvement of Cytochrome Oxidase in AD 
Clinically, AD is characterized by progressive deficits in 
memory and other cognitive functions that occur in the face 
of an otherwise normal neurological examination. Postmor 
tem examination reveals a variety of typical AD brain 
lesions, including deposition of amyloid plaques, formation 
of neurofibrillary tangles, and neuronal degeneration. The 
etiology and pathophysiology of neuronal death are 
unknown. 
There is mounting evidence that a kinetic abnormality in 
CO is likely to be involved in the progression of AD. In 
biopsy Samples from AD patients it has been shown that the 
electron transport chain is disrupted. It appears that the CO 
activity in brain and platelets of AD patients is decreased. 
Although there is a kinetic perturbation in the CO activity of 
AD patients, the concentration of CO present is normal 
(Parker and Parks, 1995; Schagger and Ohm, 1996). The 
activity of CO is decreased in the brain and peripheral tissue 
in late-onset AD. These results Suggest that the biosynthesis 
of the CO complex occurs as normal, but that there is Some 
catalytic defect. Other components of the electron transport 
chain appear to be normal in AD patients. 
CO is encoded by the mitochondrial and the nuclear 
genome. However, the catalytic centers are exclusively 
encoded by two mitochrondrial genes. Davis et al., Searched 
for mutation in the CO1, CO2 and CO3 genes (Davis et al., 
1997). They showed that CO1 and CO2 genes contain 
Specific missense mutations that may be maternally inher 
ited. Cell lines exhibiting these mutations showed a specific 
decrease in CO activity and increased production of radical 
oxygen Species. They concluded that point mutations in 
these two genes cause the CO defect in AD, and that this 
defect likely represents a primary etiological event that is 
directly involved in the cascade of events that culminated in 
clinical AD. 
Cytochrome oxidase is an important terminal component 
of the electron transport chain located in the mitochondria of 
eukaryotic cells. Cytochrome oxidase, also known as com 
plex IV of the electron transport chain, is composed of at 
least thirteen Subunits. At least ten of these Subunits are 
encoded in nuclear genes; the remaining three Subunits (I, II, 
and III) are encoded by mitochondrial genes. Mitochondrial 
DNA (mtDNA) is a small circular DNA that is approxi 
mately 17 kB long in humans. The mtDNA encodes for two 
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ribosomal RNAS (rRNA), a complete set of transfer RNAS 
(tRNA), and thirteen proteins, including the three cyto 
chrome oxidase subunits COX I, COX II, and COX III. 
2. Diagnostic ASSay for AD 
The present invention provides a cytochemical assay for 
the measurement of CO activity in individual cells. The 
assay is based on the use of calibrated tissue Standards of 
known CO activity that are measured spectrophotometri 
cally in conjunction with image microdensitometry at the 
light microScope level. 
Metabolic mapping techniqueS often use calibrated Stan 
dards. The problem of inter-assay variability largely can be 
resolved using a complete Set of CO Standards together with 
the tissue Sections in each Staining experiment. Thus, an 
internal calibration curve can be generated in each 
experiment, using the measured optical density of the Stan 
dards and their spectrophotometrically determined CO 
activity units. This is the first quantitative cytochemical 
method which allows actual microdensitometric measures to 
be expressed as enzyme activity units. 
Quantitative CO cytochemistry will be an appropriate 
mapping technique for the diagnosis, prognosis and post 
mortem analysis of human Subjects Suspected of AD. 
Mapped CO activity is theoretically related to other meta 
bolic activity-based procedures Such as fluorodeoxyglucose 
(FDG) autoradiography. This technique provides an ongoing 
index of regional brain glucose metabolism during and 
Shortly after administration of an exogenous metabolic 
marker. However, CO is an endogenous respiratory enzyme 
which, when assessed cytochemically, can illustrate the 
effect of heightened or lessened metabolic demands on the 
individual tissue over an extended period of time. Thus, 
cytochemical examination of CO activity levels and thereby 
long-term neuronal activity patterns provide a method of 
quantifying cellular metabolic differences acroSS groups of 
Subjects and various pathophysiological States. 
The cytochemical CO assay of the present invention is 
ideal for diagnosis and or prognosis of the pathophysiologi 
cal manifestation of AD as well as monitoring the effects of 
therapy of Such a State. In addition, the current assay can be 
used to follow the course of a neurodegenerative disease in 
an individual. Levels or ratios of CO activity are taken from 
the individual in a Series of correlating Samples over a period 
of time, in order to monitor changes in the values. The values 
from these Samples are compared to the control Samples 
described herein, to relate the values to those of other 
individuals with the disease, and thereby determine the 
Severity of disease. 
AS Stated above, the method also can be used to assess the 
efficacy of a drug for the treatment of AD. Levels of CO 
activity in Samples taken from an individual before the 
administration of the drug are compared to levels in a 
corresponding Sample taken from the individual after admin 
istration of the drug. These values further are compared to 
those of the control samples described herein. Efficacy of the 
drug is demonstrated if the levels of CO activity after drug 
administration are closer to AD negative (ie. increased from 
the diseased States) values than the levels before drug 
administration. 
The Sample Subjected to analysis can be selected from any 
biological tissue that possesses CO activity. It is understood 
that the present cytochemical assay may be used on periph 
eral biopsy Samples Such as Samples from muscle, dermis, 
epidermis, bone marrow, peripheral ganglion or nerve. 
Theoretical Model of the Cytochemical Reaction 
FIG. 7 is a schematic of the model of the diaminobenzi 











Riley (1989) and Seligman et al. (1968). CO is an integral 
transmembrane protein of the inner mitochondrial mem 
brane. Electrons donated from DAB reduce cytochrome c 
(Cyt C). The heme units of CO (Cyt a-a3) catalyze the 
transfer of electrons from Cyt C to molecular oxygen to form 
water. The Staining in the cytochemical reaction is produced 
when DAB is oxidized to an indamine polymer (OXID 
DAB). Since continuous reoxidation of Cyt C by CO is 
required for the accumulation of the visible OXID DAB, this 
reaction serves to visualize CO activity. The staining of the 
reaction product further is intensified by the addition of 
cobalt to the preincubation Solution (Gonzalez-Lima and 
Jones, 1994). 
The inventor's current quantitative CO method involves 
three Steps. The first Step is the preparation and Spectropho 
tometric analysis of standards. This is followed by tissue 
Sectioning and Staining protocol that is compared with 
Standards. The third Step involves imaging of the Stained 
tissue Slides. These Steps are described in detail herein 
below. 
Preparation of Standards and Spectrophotometry 
CO activity standards are made from the brains and 
peripheral tissueS of a control animal, for example rat, 
monkey or even human. Tissues are homogenized at 4 C. 
and aliquots are frozen and Sectioned at varying thickness to 
develop a gradient of CO activity in the Sections to be used 
as Standards. Standards are Stained together with tissue 
Sections to generate a calibration curve between Standard 
CO activity and optical density in the tissue. 
CO activity in the Standards is spectrophotometrically 
measured with modified methods adapted from Wharton and 
Tzagoloff (1967), Hevner et al. (1993) and Cada et al. 
(1995), with modifications detailed below. Activity units 
were defined at pH 7 and 37 C. as 1 unit oxidizes 1 tumol 
of reduced cytochrome c per min (umol/min/g tissue protein 
weight). 
Detailed protocol: 
This protocol describes the generation of a CO standard 
curve. CO Standards are generated from the tissues of 
control animals. In Specific embodiments, the tissues may be 
brain Samples from control animals. Such as male rats. 
However, it is understood that the Standard Samples may be 
derived from any animal. The tissues are rapidly removed 
and stored in an appropriate buffer at 4 C., pH 7.4. The 
tissue is then homogenized at 4 C., divided into Small 
aliquots, spun briefly in a 4 C. centrifuge to remove air, and 
frozen in -40° C. 
To measure CO activity spectrophotometrically in the 
paste Standards, a Solution of 1.0% cytochrome c in potas 
sium phosphate buffer (pH 7.0) is reduced with sodium 
ascorbate (indicated by a color change) (Cada et al., 1995, 
Gonzalez-Lima and Jones, 1994). Other small percent con 
centrations of cytochrome c also may be used but require 
recalibration with each kind of tissue used. The important 
point is to have excess cytochrome c So that the limiting 
factor in the reaction is CO activity. Other reducing agents, 
Such as Sodium hydroSulfite, may be used instead of Sodium 
ascorbate. The exceSS reducing agent is removed by dialysis 
against potassium phosphate buffer for 24h (three changes) 
at 4 C. This working concentration of cytochrome c is about 
0.07% cytochrome c in 0.05 M potassium phosphate buffer. 
The tissue homogenate is Suspended in isolation buffer 
and chilled on ice. In preferred embodiments, approximately 
1 g of tissue paste is Suspended in 4 ml isolation buffer. The 
assay mixture contains final concentrations of 0.25% (w/v) 
tissue and 0.5% (w/v) sodium deoxycholate. For the assay, 
an aliquot of the assay mixture and an aliquot of the working 
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concentration of cytochrome c are reacted together at 37 C. 
In order to monitor the CO activity, the change in absor 
bance at 550 nm is monitored. Activity units are defined at 
pH 7 and 37 C. as in the inventor's original quantitative 
method (Gonzalez-Lima and Garrosa, 1991) wherein 1 unit 
of CO oxidizes 1 umol of reduced cytochrome c per min 
(umol/min/g tissue wet weight). 
TiSSue Sectioning and Staining 
Frozen tissue are Sectioned at 40 um and picked up on 
clean slides in a Frigocut 2800 cryostat at -15 C. Slides are 
processed for CO quantitative cytochemistry similarly as 
described in Cada et al. (1995) with modifications detailed 
below. Preincubation solution is followed by incubation at 
37 C. for 60 min. 
In preferred embodiments, Slides may be treated to facili 
tate adherence of the tissue Sections and Standards to the 
Slides. The tissue Section may be washed with appropriate 
buffers. A preincubation step is included in which the slide 
is placed in cobalt chloride or another metal Salt, to intensify 
tissue staining. The following is a detailed protocol for the 
materials and methods used in the Staining procedure. 
Detailed Protocol 
Preferred Materials 
1) Phosphate buffer from stock solutions (0.1 M monoba 
sic and dibasic) in a ratio of 100 ml monobasic to 900 
ml dibasic, and adjusted until pH 7.4. 
2) Tris buffer is a mixture of 500 ml 0.2M Tris base, 774 
ml 0.1N HCl and H2O to 21. To this add 550 mg cobalt 
chloride, 200 g sucrose and 10 ml DMSO. The phos 
phate and Tris buffers can be kept refrigerated for 
Several days if color does not change. 
3) The DAB solution for a 100 ml bath is made with 50 
mg DAB (3,3'-diaminobenzidine tetrahydrochloride, 
Sigma), 7.5 mg cytochrome c (from horse heart, 95% 
minimum purity, prepared using TCA, Sigma), 5 g 
Sucrose, 2 mg catalase (from bovine liver, 2,000–5,000 
units activity/mg protein, Sigma), 0.25 ml DMSO, and 
phosphate buffer added to make 100 ml. The DAB 
incubation Solution must be made fresh each time. Both 
the preincubation and incubation Solutions must be 
renewed after each rack of Slides is run through them. 
4) The staining baths can be done conveniently in large 
glass Staining dishes with a rack of Slides. This is 
important to try to Stain the same regions for Sample 
and controls in a Single incubation to minimize inter 
Staining variation. 
5) Two or more complete sets of CO standards should be 
Stained in each incubation bath. 
Preferred Procedure 
Sections should be kept frozen until placing in the 
Sequence of baths and times listed below. 
1) Cold buffered 0.5% glutaraldehyde in 0.1 M pH 7.4 
phosphate buffer (4 C.) to affix sections, 5 min. 
2) 0.1 M phosphate buffer with 10% sucrose (in four 
changes), 5 min each 
3) Preincubation with Tris buffer and additives, 10 min 
4) 0.1 M phosphate buffer rinse 
5) Incubation with DAB solution (preceded by 5 min of 
oxygen bubbling) at 37°C. with automatic stirring in a 
dark oven, 120 min 
Diaminobenzidine and cytochrome c are essential to the 
reaction. Sucrose facilitates protection of cell membranes. 
DMSO is presumed to involve enhancing penetration of the 
reagents into the cells (DeClimos and Heimer, 1977). DMSO 











results. But these additives are effective only in the prein 
cubation step (i.e., before the CO incubation reaction). 
Addition to the incubation reaction medium of DMSO 
(Kugler et al., 1988), and cobalt (Nobrega, 1992) offers little 
gains. Furthermore, metal intensification during incubation 
affects conditions necessary for quantification of CO activ 
ity. Catalase may be omitted without much deleterious 
effects. Catalase is a heme-containing protein that catalyzes 
the dismutation of hydrogen peroxide into water and 
molecular oxygen. Hydrogen peroxide is a normal product 
of oxygen respiration; thus the breakdown of these mol 
ecules has a two-fold advantage of preventing both inter 
ference by the free-radical in enzyme activity as well as the 
addition of molecular oxygen to the Substrate. 
With 40 micron sections, the reaction is conducted in a 
closed oven at 37° C. (measured inside the incubation 
solution) for 60-120 min for optimal quantitative results in 
human tissues. To Stop the reaction and fix the tissue, slides 
are immersed in a buffer containing 4% formalin (v/v). The 
fixed Samples are then dehydrated, cleared using for 
example Xylene, and coverslipped with Permount. 
Microscopic Image Analysis 
Stained tissue Slides were mounted on an light microscope 
connected to an imaging System. A high resolution CCD 
Video camera mounted on the microScope is used to capture 
the images and transmit them to a frame grabber in a 
computer where the image is digitized. Analysis is com 
pleted with Jandel Scientific imaging Software. 
Detailed Protocol 
Stained tissue slides are mounted on an Olympus light 
microscope (model BX40) connected to an image process 
ing System. The same microScope lamp intensity level is Set 
and Verified densitometrically throughout the Study, and 
condenser centration is performed prior to each imaging 
Session to ensure that illumination levels are equivalent for 
the measurement of optical density. 
A high resolution CCD video camera (Javelin JE-7442) is 
mounted on the microscope to capture the images and 
transmit them to a frame grabber (Targa M8) mounted in a 
computer where the image is digitized. Analysis is com 
pleted through the use of imaging Software. 
The recommendations of Chieco et al. (1994) are fol 
lowed to avoid photometric errors in image cytometry. 
These recommendations are listed herein as follows. A clear 
background from a mounted Slide is Subtracted from each 
image to correct for lens and camera anomalies and shading 
distortion. An interference glass filter is interposed in the 
microScope light path to correct for white light distortion. 
The brightest pixel of the image is maintained a few gray 
levels below Saturation to correct for blooming caused by 
excessive light. On the Video camera, the automatic gain is 
Switched off and the gamma control Switched on to obtain 
gray levels linear with transmission. A 40x objective is used 
and Sections Stained lightly to avoid distributional error, 
glare, and diffraction errors. Pixel Spacing may be calibrated 
with a Stage micrometer Separately for vertical and horizon 
tal dimensions. 
For spatial calibration, the JAVA Software may be used in 
the computer to load conversion values into comparison 
tables. A calibration Strip containing various gray levels of 
known optical densities (Kodak) can be imaged at the 
beginning of each Session and used to construct a calibration 
curve for the conversion of gray levels to optical density for 
that Session. Each imaging Session is thus independently 
calibrated to optical density. 
3. Definition of CO Activity Units 
Besides differences in the preincubation and incubation 
histochemical protocols, there are factorS Such as tempera 
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ture and pH related to the conditions used during biochemi 
cal enzymatic determination and the calculation of CO 
activity units. These relevant factors, however, are usually 
not all reported in previous enzymatic activity studies (Benzi 
et al., 1979; Curti et al., 1990; Darriet et al., 1986; Hess and 
Pope, 1953; Van Raamsdonk et al., 1987) making compari 
Sons of absolute activity units complicated. The temperature 
of the reaction medium, for instance, would influence the 
Speed of CO reaction product formation and calculated rate 
of activity. 
The inventor has reported CO units measured spectro 
photometrically at both 22 C. (standard room temperature) 
(Gonzalez-Lima and Cada, 1994) as well as at 37° C. 
(Gonzalez-Lima and Garrosa, 1991; Cada et al., 1995). For 
routine measures, Solutions at 22 C. are more stable; that is, 
they show little auto-oxidation as compared to 37 C., which 
facilitates reproducibility of multiple triplicate assays from 
the same stock solutions. While Hess and Pope (1953) also 
have measured activity at 22 C., they have converted 
activity to 37 C. by multiplying units by a factor of 3, 
assuming CO activity to be doubled per each 10 C. rise in 
temperature. The inventor has not found this assumption to 
be valid. The definition of CO activity units using optimal 
reaction conditions for Spectrophotometry, Such as pH 7 at 
37 C., may be preferable for studies evaluating absolute CO 
activity, rather than simpler routine assays (Hess and Pope, 
1953) done at room temperature in which CO units can be 
defined reliably but at below maximal levels (Gonzalez 
Lima and Cada, 1994). 
An ideal Situation is for all investigators to use the same 
conditions to define a unit of activity, and to consistently 
report data under these conditions. Alternatively, the activity 
from a whole-brain homogenate or a similar reference may 
be reported to provide a relative index of the enzymatic 
activity obtained under different measurement conditions. 
For example, homogenates of fresh-frozen rat brains showed 
an average CO activity of 175 units (umol/min/g tissue w/w) 
in the assay conditions reported below. This average CO 
activity units in the control brains was very similar to the 
average CO activity in the whole rat brain (158+5) reported 
by Hevner et al., (1993). The present somewhat higher value 
may be attributed to the fact that the CO units herein were 
defined at pH 7 and 37 C., as in the original method 
(Gonzalez-Lima and Garrosa, 1991), as opposed to pH 6 and 
30° C. as done by Hevner et al. (1993). The agreement 
between these control brain CO values suggests that both 
assays were optimal in unmasking enzyme activity to maxi 
mal or near maximal levels (Hevner et al., 1993). Whether 
the units are defined based on tissue wet weight (w/w) or dry 
weight needs also to be specified (Nobrega et al., 1993). The 
present activity units showed good agreement with values 
reported in the literature when Similar conditions were used 
to measure and define the units of CO activity. 
For those interested in reporting a relative CO 
quantification, without measurement of enzyme activity 
units, comparisons using relative indexes. Such as whole 
brain or white matter as references may be useful. Reporting 
relative densitometric ratios, Such as is done in 2-DG Studies 
(e.g., Gonzalez-Lima and Scheich, 1984) is a useful 
approach that may suffice for many CO applications (e.g., 
Jones et al., 1997). It is valid to quantify relative values, as 
long as one does not presume that they represent absolute 
values. However, it should be cautioned that if a CO 
histochemical procedure fails to meet the quantitative 
requirements of linearity of reaction product formation with 
respect to incubation time and Section thickness, it can not 
be used as a valid quantitative method with relative mea 











Preincubation Metal Intensification with Tris Buffer and 
DMSO 
Metal intensification with cobalt chloride, nickel ammo 
nium Sulfate or manganese chloride has been shown to 
enhance the Sensitivity of detecting benzidine reaction prod 
ucts in HRP histochemistry (Adams, 1977; DeClimos and 
Heimer, 1977). Ten min with a preincubation solution of 
0.05M Tris buffer at pH 7.6, containing cobalt chloride and 
DMSO similar to that of Adams (1977) and DeOlmos and 
Heimer (1977), has increased the sensitivity of CO his 
tochemistry over that of Wong-Riley's (1979) protocol with 
out loss of specificity (Silverman and Tootell, 1987). The 
inventor confirmed this enhanced Sensitivity in CO Staining 
of rat brains when incorporating this preincubation Step in 
the inventor's original quantitative histochemical procedure 
(Gonzalez-Lima and Garrosa, 1991). 
The positive action of preincubation with cobalt chloride 
is seen in the formation of a darker reaction product, which 
may involve polymerization of the initial DAB reaction 
catalyzed by cobalt chloride. ExceSS precipitate is elimi 
nated by repeated changes in phosphate buffer to remove the 
cobalt Salts not incorporated into the mitochondrial reaction 
product (Silverman and Tootell, 1987). The inventor has 
repeatedly confirmed this cobalt-enhanced Sensitivity and 
Specificity in the CO Staining of tissues from many different 
Species, including humans (Gonzalez-Lima et al., 1997). 
The use of maximal metal intensification during the 
incubation reaction facilitates morphological visualization 
of reaction product in all neurons (Kageyama and 
Robertson, 1993; Liu et al., 1993). However, using metal 
intensification procedures during incubation invalidate the 
quantitative requirements of graded reaction product reac 
tivity proportional to CO enzymatic activity. That is because 
maximal intensification results in Saturation of reaction 
product formation and Similar dark Staining of cells with low 
and high CO activities. If the objective of the CO stain is to 
obtain a quantitative functional index of CO activity, rather 
than a morphological indeX with Saturated Staining, then 
metal intensification is better used as a preincubation Step 
rather than during incubation. In this manner, the incubation 
reaction can proceed undisturbed using parameters that 
result in nonsaturated reaction product formation in a rate of 
reaction linear with respect to increasing incubation time. 
For the same reason, CO histochemical procedures which 
yield reaction rates different during the first min and Sub 
Sequent period of incubation (e.g., Kugler et al., 1988) are 
also invalid for quantitative CO histochemistry. 
Temperature, pH, Oxygenation and Duration of the CO 
Incubation Reaction 
DeOlmos and Heimer (1977) were able to increase the 
sensitivity of HRP histochemistry by manipulating intrinsic 
factors of the incubation reaction Such as pH and tempera 
ture. Silverman and Tootell (1987) similarly improved CO 
Staining intensity by increasing pH, temperature, and adding 
oxygen to the incubation medium. The Standard Spectropho 
tometric assay of CO developed by Wharton and Tzagoloff 
(1967) uses pH 7 at 37° C. for optimal CO activity in vitro. 
Although pH 7 appears optimal for biochemical assays of 
CO activity in separated mitochondria in vitro, pH 7.6 
improves the histochemical Staining facilitating entry of the 
reagents by Swelling of tissue mitochondria in Situ 
(Silverman and Tootell, 1987). Higher temperatures also can 
accelerate the CO reaction, but when using internal activity 
standards in the present quantitative method, a 37 C. 
temperature showed the best linearity between densitometric 
measures of Staining intensity and incubation time. 
Silverman and Tootell (1987) also found that oxygen 
Saturation of the incubation medium improved CO Staining 
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by increasing DAB oxidation to form the colored reaction 
product. However, the inventor has found that Saturation is 
best done before the introduction of the rack of slides with 
the Sections. 
This is because oxygen bubbling during the reaction 
causes a differential distribution of bubbles in the Solution 
that results in nonuniform staining of adjacent Slides 
(Gonzalez-Lima, 1992). Gentle agitation with a stirrer bar 
throughout the reaction and ample circulation between, 
above, and below the slides prevents the formation of a 
Staining gradient by circulating the oxygen and reagents 
thoroughly. Exposure of the reaction medium to intense light 
needs to be avoided because it may produce Spontaneous 
DAB Oxidation leading to nonspecific Staining. 
4. Kits 
The present invention also relates to methods of identi 
fying and quantitating AD in a tissue and kits for use therein. 
The kits of the present invention will provide all the com 
ponents necessary for a CO assay of the present invention. 
In this aspect, the present invention contemplates diagnostic 
kits for the determination of CO activity in a tissue sample. 
Said kits will likely contain the active Standards and Staining 
agents used in the present invention. 
The kits also may include reagents necessary for the 
preparation of Samples for a cytochemical analysis. AS Such 
it is contemplated that all the reagents necessary for pro 
cessing a tissue Sample will be included in a kit of the 
present invention. 
The kits of the invention will generally comprise one or 
more Standard tissues having a defined CO activity. 
Preferably, the kits will comprise, in Suitable container 
means, one or more Standard tissues Selected from the group 
consisting of muscle, dermis, epidermis, bone marrow, 
peripheral ganglion or nerve of a non-AD origin for com 
parison with biopsy samples that will be taken from AD 
individuals. Alternatively, the kits may have a preparation 
comprising cytochrome oxidase. 
Preferred kits are those Suitable for use in a microscopic 
cytochemical assay. Also included in the kits may be 
reagents and buffers to provide the necessary reaction mix 
ture for the cytochemical assay. 
The kits of the present invention, also may contain a panel 
of calibration Strips containing various gray levels of known 
optical densities to be used to construct a calibration curve 
for the conversion of gray levels to optical density for each 
Session. 
In each case, the kits will preferably comprise distinct 
containers for each individual reagent and enzyme. Each 
biological agent will generally be Suitable aliquoted in their 
respective containers. 
The container means of the kits will generally include at 
least one vial or test tube. FlaskS, bottles and other container 
means into which the reagents are placed and aliquoted are 
also possible. The individual containers of the kit will 
preferably be maintained in close confinement for commer 
cial Sale. Suitable larger containers may include injection or 
blow-molded plastic containers into which the desired vials 
are retained. Instructions may be provided with the kit. 
5. Examples 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 











that many changes can be made in the Specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the Spirit and Scope of the invention. 
EXAMPLE 1. 
Materials and Methods 
Human Subjects 
Frozen tissue samples were received from the Alzhe 
imer's Disease Research Center Neuropathology Core at the 
University of Southern California School of Medicine and 
from the Brain Bank of the Michigan Alzheimer's Disease 
Research Center at the University of Michigan Medical 
Center. 
Tissue samples were stored at -40 C. until processing. 
The non-AD, non-demented control group consisted of 5 
males and 3 females with a mean age of 79.6+3.1 years, a 
mean post-mortem interval of 6.9-1.6 h, and a mean brain 
weight of 1287.5+39.8 g. Non-AD cases died of cardiores 
piratory failures or cancer. The AD group consisted of 7 
males and 1 female with a mean age of 78.3+2.9 years, a 
mean post-mortem interval of 6.5-t1.3 h., and a mean brain 
weight of 1175.0+50.9 g. 
Patients reports included years Since diagnosis of AD 
dementia (mean=8.6t1.1 years) and confirmation of AD 
histopathology. Six AD patients died of cardiorespiratory 
failure, but a cause of death other than AD was unavailable 
for the other two. The available drug histories showed no 
neuroleptic use. Student's two-tailed t-tests demonstrated no 
Significant differences between the control group and the AD 
group in age (p>0.75), post-mortem interval (p>0.84), and 
brain weight (pa0.10). 
TiSSue Processing 
Human brain tissue was Sectioned at 40 um in the trans 
verse plane and picked up on clean Slides in a Frigo-cut 2800 
cryostat at -15 C. Slides were processed for CO quantita 
tive cytochemistry as in our previously described his 
tochemical procedures (Gonzalez-Lima, 1992; Gonzalez 
Lima and Cada, 1994, Gonzalez-Lima and Garrosa, 1991; 
Gonzalez-Lima and Jones, 1994) which were based on 
similar staining procedures (Silverman and Tootell, 1987; 
Wong-Riley, 1979). Preincubation (Adams et al., 1977) was 
followed by incubation at 37 C. for 120 min. Adjacent 
sections were stained with Cresyl violet to delineate the 
cytoarchitecture of the IC. 
Spectrophotometric ASSessment of Cytochrome Oxidase 
Activity 
CO activity standards were made from the brains of 12 
adult male rats. Each animal was decapitated, its brain 
rapidly removed and stored in 4 C. sodium phosphate buffer 
(pH 7.4) until all 12 brains were collected. The brains were 
homogenized at 4 C. and aliquots were frozen in 1.5 ml 
microtubes and Sectioned at varying thicknesses to develop 
a gradient of CO activity in the Sections used as Standards. 
Sections of the standards were stained together with the IC 
Sections for the generation of a regression equation between 
Standard CO activity and optical density in the tissue in each 
Staining batch (Gonzalez-Lima and Jones, 1994). 
CO enzyme activity in the Standards was spectrophoto 
metrically measured using a method adapted from Wharton 
and Tzagoloff (1967) and Hevner et al. (1993) as reported in 
Cada et al. (1995). Activity units were defined at pH 7 and 
37 C. as in our original quantitative method (Gonzalez 
Lima and Garrosa, 1991) where 1 unit oxidizes 1 umol of 
reduced cytochrome c per min (umol/min/g tissue wet 
weight). Activity units can also be expressed in terms of 
grams of protein content (Lowry et al., 1951) by multiplying 
the reported values by 10 Since our brain Standards con 
tained an average of 10% protein (Gonzalez-Lima and Cada, 
1994). 
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Microscopic Image Analysis 
Stained tissue slides were mounted on an Olympus light 
microscope (model BX40) connected to an image process 
ing System. The same microScope lamp intensity level was 
Set and Verified densitometrically throughout the Study, and 
condenser centration was performed prior to each imaging 
Session to ensure that illumination levels were equivalent for 
the measurement of optical density. A high resolution CCD 
video camera (Javelin JE-7442) was mounted on the micro 
Scope to capture the images and transmit them to a frame 
grabber (Targa M8) mounted in a 486 computer (Dell) where 
the image was digitized. 
Analysis was completed through the use of JAVA (Jandel 
Scientific) imaging Software as described elsewhere in the 
specification. The recommendations of Chieco et al. (1994) 
were followed to avoid photometric errors in image cytom 
etry. 
A calibration Strip containing various gray levels of 
known optical densities (Kodak) was imaged at the begin 
ning of each Session and was used to construct a calibration 
curve for the conversion of gray levels to optical density for 
that Session. Each imaging Session was thereby indepen 
dently calibrated to optical density. Thickness Standards of 
known CO activity (measured spectrophotometrically) were 
included in each Staining batch and were imaged on a 
DC-powered light box using JAVA as described previously 
(Gonzalez-Lima et al., 1993). The optical density and activ 
ity measurements of these Standards were then used to 
construct a regression equation. 
The change in optical density showed linear relationships 
with respect to tissue activity, Section thickness, and incu 
bation time in each of the three Staining batches done 
(r=0.96, 0.97, and 0.97). Optical density measures of the IC 
Sections were thereby independently converted to CO activ 
ity units using the calibration curves generated with the 
Standards optical density and activity units. 
A total of 480 cells were sampled consisting of 30 cells 
per subject for 16 subjects. The inferior colliculus was 
subdivided into three separate nuclei: the central (ICC), 
dorsal (ICD) and external (ICE). To avoid mistakenly sam 
pling from outside the intended nucleus, observations were 
restricted to the central part of the IC subdivisions, within 
the perimeters denoted in FIG. 1. 
Ten cells were Sampled randomly per nuclear Subdivision 
per Subject from up to 8 Sections with Sections Sampled 
Separated by at least a 120 um interval. Additional Selection 
criteria for Sampling were that tissue was free from artifacts 
of Staining and tissue processing (Such as cracks, folds, and 
foreign particles) and that cells showed no obvious signs of 
morphological abnormalities (such as vacuolations, den 
dritic Swellings, eccentric nuclei, etc.). All measurements 
were taken by a Single observer. A total of 8 densitometric 
and 6 morphometric measures were taken from each cell; for 
these measurements the cell body was oriented in the center 
of the image area (FIG. 2). All measurements were taken 
using JAVA (Jandel) software, as follows: 
Overall average: with the cell body in the center of the 
image area, the CO activity was averaged acroSS the entire 
rectangular image area (165x130 um). This area included 
primarily the neuropil that Surrounded each Single cell 
Sampled, the cell body, and capillary Space. 
Neuropil peakS: the three highest points of peak activity 
in the neuropil of each rectangular image area of 165x130 
tim were Selected and measured. Each peak was measured 
by averaging an area contained within a 13x13 pixel (5x5 
pum) window. 
Perikaryon average: the average activity of the cell body, 











by outlining the perimeter of the cell body and nucleus and 
averaging the interior of that outline. 
Perikaryon peak: the point of highest activity in the 
perikaryon; the average of a 5x5 pixel (2.4x2.4 um) window. 
Primary branch peak: the point of highest activity in the 
primary branch of the largest arborizing process, the average 
of a 5x5 pixel window. 
Primary branch average: the average activity of the above 
primary branch, measured by outlining the branch from the 
cell body to the first visible Secondary branch and averaging 
the activity within. 
Secondary branch peak: the point of highest activity in a 
Secondary branch of the largest arborizing process; the 
average of a 3x3 pixel (1.7x1.7 um) window. 
Secondary branch average: the average activity of the 
above Secondary branch, measured by outlining the branch 
from the primary branch to the first visible tertiary branch 
and averaging the activity within. 
Soma diameter: diameter was measured perpendicular to 
the axis of the primary branch. 
Soma area and perimeter: including the nucleus and 
excluding any processes; measured by outlining the cell 
body. 
Nucleus diameter: again, measured perpendicular to the 
axis of the primary branch. 
Nucleus area and perimeter: including only the nucleus of 
the cell; measured by outlining the nucleus of the cell. 
EXAMPLE 2 
Early Diagnosis of AD Using Deltoid Muscle 
Biopsy 
A preferred method of monitoring AD in an individual is 
to detect CO activity inhibition in deltoid muscle biopsies as 
an early diagnostic aid in patients Suspected of AD. A needle 
is inserted in the back of the shoulder with local anesthesia 
and a Small (2 mm cubic) muscle Sample is aspirated and 
processed for CO activity as described above. 
Since the brain relies almost exclusively on the aerobic 
metabolism of glucose for its energy (Sokoloff, 1989), CO 
function is essential for normalbrain function. But CO is the 
terminal rate-limiting enzyme for cellular respiration in all 
eukaryote cells, Suggesting that a Systemic CO deficiency 
may be detected in AD nonneural cells. 
Therefore, the quantitative CO method can be applied in 
a laboratory biopsy assay for diagnosis of late-onset, Spo 
radic AD in a peripheral tissue. 
Skeletal muscle was studied first because of its rich 
Supply of mitochondria and well-established use in diagnos 
tic enzyme histochemistry of neuromuscular diseases 
(Bauserman and Heffner, 1984). Apolipoprotein E (ApoE)- 
epsilon4 allele, associated with familial AD, has been found 
in skeletal muscle (Akaaboune et al., 1994). It has also been 
documented that CO reactivity decrements can be detected 
in muscle with routine histochemistry in some childhood 
genetic diseases caused by CO deficiencies that lead to 
neurodegeneration, Such as Leigh's (Subacute necrotizing 
encephalomyelopathy) and Alper's (progressive infantile 
poliodystrophy) diseases (Sarnat, 1983). So it is reasonable 
to assume that the inventor's more Sensitive histochemical 
method used in older patients, with clinical manifestations 
of dementia, may serve as a differential diagnostic aid for 
sporadic AD. This could be done by confirming that the 
Suspected patients have peripheral tissue CO activity 
decreases such as the 17% to 50% found in AD platelets 
(Parker et al., 1990, 1994a). 
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Samples from deltoid muscle are particularly well-Suited 
to examine CO activity because they normally contain a 
predominance of Type I fibers. The two basic muscle fiber 
types in humans are Type I or red fibers and Type II or white 
fibers. The red fibers are primarily oxidative, while the white 
fibers are primarily glycolytic. AS compared to white fibers, 
red fibers contain many more mitochondria and higher 
concentrations of oxidative enzymes (Sarnat, 1983). Thus, 
red fibers stain dark and white fibers stain light with the 
present CO histochemical method. 
The inventor studied deltoid muscle samples from 12 
Subjects using quantitative CO histochemistry. Six of the 
Subjects were late-onset AD cases with histopathologically 
confirmed AD, and the other Six Subjects were aged normal 
controls. There were four females and two males in each 
group. Their mean (it standard error) age was 83 (t2.4) and 
the postmortem time before freezing of the Samples was 
50.8 h. 
There were no significant (p<0.05) group differences in 
age and postmortem time. But the groups showed clear 
Significant differences in mean CO activity. The aged con 
trols had 51.30+6.57 units of CO activity, whereas the AD 
subjects had 29.18+5.22 units. This corresponded to a sig 
nificant (t-test, P=0.0249) mean decrease of 43% in the AD 
Subjects. 
Additionally, none of the AD cases showed CO activity 
values greater than the mean of the aged controls. These 
results Suggest that muscle biopsy may be used as an early 
diagnostic aid in living Subjects Suspected of Sporadic AD. 
An early diagnostic lab test of AD may facilitate a more 
effective medical treatment for the majority of AD cases, 
which are of the sporadic type. Monitoring of CO activity 
using muscle needle biopsies may also serve to evaluate the 
Success of early treatments in reversing this enzymatic 
defect to prevent oxidative StreSS leading to neurodegenera 
tion. 
These data also Support the hypothesis that Sporadic AD 
is a Systemic mitochondrial disease, characterized by CO 
inhibition. Furthermore, the finding of CO inhibition in 
peripheral tissueS of AD patients has implications for the 
pathogenesis of AD. For example, it may be possible to 
argue that a decrease in CO activity observed in neurons is 
a nonspecific consequence of any neurological disease lead 
ing to cerebral hypometabolism. 
However, a condition Such as cerebral vascular changes, 
brain trauma, or other causative factors of brain hypome 
tabolism are unlikely to explain a peripheral defect in CO 
activity as found in platelets by Parker et al. (1994b) or in 
muscle by us. The most parSimonious explanation is that 
early in sporadic AD the inhibition of neuronal CO activity 
is caused by a Systemic CO defect, rather than by nonspe 
cific hypometabolic conditions following ischemia or other 
neurodegenerative processes. In this context, the brain 
would be the most Vulnerable organ to Show primary patho 
genesis as a result of Systemic CO inhibition. Neurons are 
more Vulnerable to show CO-dependent pathophysiology 
than other tissues because the brain is rich in lipids Vulner 
able to peroxidation and it has higher oxygen consumption, 
but the brain has less antioxidant defenses than other tissues 
that are leSS active aerobically. 
EXAMPLE 3 
Morphometry of CO-stained Neurons 
Overall, the number of CO-stained cell bodies in the IC 











bodies Seen per CO-stained Section on average, as counted 
with the optical dissector approach (West, 1993). Micro 
Scopic imaging of CO-Stained cell bodies revealed high CO 
activity in the perikaryon (average of 607.7 activity units). 
Thus, Stained cell bodies typically presented themselves as 
Golgi-like images consisting of a dark perikaryon with a 
light-colored or clear ovoid or spherical center, which was 
the unstained mitochondrion-less nucleus of the cell (FIG. 
2). 
Most of the cells also had variably stained processes 
which were nearly always determined to be dendritic, Since 
the axon takes little or no Stain and is, hence, usually 
invisible. Some of the processes could occasionally be 
observed to extend over 100 um from the Soma of the cell. 
The cellular organization of the IC revealed with CO 
Staining followed closely the descriptions of the cells of the 
inferior colliculus made by Cajal (1995). The measurements 
reported here from a sample of 80 cells from each of the 
three nuclei in the control subjects showed a distribution of 
the diameters of the Sampled cell bodies similar to and 
approximating Cajal's Size categorization. Frequency histo 
grams were constructed for each variable for each IC 
nucleus in the control group. ICC Soma diameter demon 
strated a clear bimodal distribution (FIG. 3). Therefore, 
Subsequent comparisons of CO activity variables were also 
made between larger and Smaller cell Subgroups classified 
by the mean of the control group's ICC Soma diameter, 12.1 
tim. The topographic distribution of the larger cells in the IC 
is illustrated in FIG. 1C, which shows that they are more 
abundant in the ICC. 
Neuronal Soma and nucleus area, perimeter, and diameter 
were all significantly larger in the ICC as compared to the 
ICD and ICE (meani-S.E.M. morphometric values are 
shown in FIG. 4). This is consistent with the observation that 
the largest overall stained cells were found in the ICC. 
The mean Soma diameter in the ICD was 8.94+0.61 um, 
as compared to 12.09+0.77 in the ICC, with nearly all the 
cells in the Small to medium range and very few large cells. 
Cajal referred to the ICD as the internuclear or dorsal 
cortex or 'tectum, and described this region as laminated. 
However, these laminations are not readily apparent in a CO 
Staining, either under macro- or microimaging conditions. 
The mean Soma diameter in the ICE measured 9.12+0.45 
lum. Cajal termed the ICE as the lateral or external cortex 
of the inferior colliculus. Most of the cells sampled fell into 
the Small range, with Some medium-sized, and few large. 
Cajal reported a lateral row of Small cells. These were 
approximately 8-10 um in diameter, with triangular, Stellate, 
or fusiform shapes. A more medial row of medium-sized 
cells showed neurons. Somewhat larger, approximately 8-14 
tim in diameter, with the majority being triangular and 
pyramidal shapes, with two or more thick dendrites ema 
nating from the Some 
EXAMPLE 4 
CO Activity in Control Neurons 
Mean values of CO activity in the control group are 
shown in FIG. 5. Each bar represents the mean tS.E.M. of 
the 8 non-AD control Subjects. The subject score consisted 
of the mean of the measurements from the 10 cells sampled 
in each division of the IC. That is, 80 cells per division of 
the IC, and a total of 240 cells sampled for the three 
divisions. Comparisons of CO activity between the IC nuclei 
were made using a one-way analysis of variance with a 
post-hoc Student-Newman-Keuls test at the 0.05 signifi 
cance level (SPSS software). 
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The mean overall average CO activity for cells in both the 
ICC (183.40+18.77) and ICD (184.98+45.08) was signifi 
cantly higher than in the ICE (56.46+15.94). It should be 
noted that the external nucleus merges laterally with the 
brachium of the IC, and the myelinated fibers projecting 
from the ICC to the brachium pass through the ICE and may 
have contributed to this low overall reading. However, the 
mean comparisons also showed that both the cell perikaryon 
average and peak activities were Significantly higher in the 
ICE (742.731+67,902 and 1034,065+83.932) relative to the 
ICE (462.446-4+52.047 and 708,870+64.085). 
One-way ANOVA comparisons between the large and 
Small cell Subgroups acroSS the entire IC showed that the 
larger cells (>12.1 um in diameter) contained higher CO 
activity as revealed in their perikaryon average (p<0.001), 
perikaryon peak (p<0.002), and primary branch peak 
(p<0.02) measures. This is consistent with the view that 
large cell bodies tend to be of projection neurons Supporting 
greater processes that require higher metabolic demands. 
EXAMPLE 5 
Comparison with Neurons of AD subjects 
The same morphometric and CO activity measurements 
done with the 8 controls (n=240 cells) were made with the 
8 AD Subjects (n=240 cells), matched by age and postmor 
tem time, and the results were compared for each measure. 
No morphometric differences were found between AD and 
control measures. The activity measurements from the AD 
tissue did not differ significantly from the controls when 
large and Small cells were combined in the analysis (one 
way ANOVA; SPSS software). However, the large AD cells 
in the ICC (n=35), as compared to the control cells (n=37), 
were deficient in CO activity in the overall average 
(p<0.032) and neuropil peaks (p<0.012) measures (FIG. 6). 
This corresponded to a 17.7% decrement in overall average 
activity and a 10.3% decrement in peak neuropil activity. No 
Significant activity differences were found in the Small cell 
Subgroup. 
EXAMPLE 6 
Methodological Validation of Quantitative CO 
Cytochemistry 
Peripheral and brain tissues from rats and humans were 
stained with the CO technique of the present invention (FIG. 
8A-FIG. 8H). 
For the validation of activity Standards, Samples of each 
Standard were assayed for calculation of Specific activity 
Spectrophotometrically. Percent weight of Standards was 
related to assessed activity. The relationships between time 
of incubation, Section thickness, and activity of dissected 
regions, with their reaction product measured densitometri 
cally were demonstrated. After Systematically varying 
parameters for the assays, peripheral tissue and brain Stan 
dards were developed which showed a linear relationship 
(r=0.999) between CO activity (activity units) and CO 
reactivity (O.D. units) (FIG. 9). 
Heart ventricular muscle was used because it is the tissue 
with the highest CO activity. A rat brain homogenate did not 
exhibit as much CO activity as the most active regions of the 
brain including auditory nuclei. Therefore, when using Stan 
dards with leSS activity than whole-brain homogenates, it is 
necessary to extrapolate CO activity units above the range of 
observations made to include the brain structures with the 











thicknesses Served to obtain increasing proportions of CO 
reactivity. This was the most convenient method when used 
with the CO cytochemical procedure described above 
because it resulted in a rate of reaction linear with respect to 
increasing incubation time (FIG. 10) and Section thickness 
(FIG. 11). 
The calibration procedure for the conversion of densito 
metric measures of reaction product (O.D.) to spectropho 
tometric measures of enzyme activity units was further 
Verified by comparison of dissected brain regions analyzed 
Spectrophotometrically with the converted units obtained in 
Stained tissue Sections. The measured activity units were 
linearly correlated (r=0.96) with the O.D. of histochemical 
stain (Gonzalez-Lima and Jones, 1994), similar to the find 
ings with the tissue Standards. 
The quantitative cytochemical method as proposed here 
provides a good indicator of fresh tissue CO enzymatic 
activity (i.e., without a Substantial fixation inhibition) 
because preincubation fixation is limited to 5 min with 0.5% 
glutaraldehyde. The inventor has directly assessed the effect 
of this preincubation fixation Step by comparing adjacent 
Sections from the same tissue Standards that either remained 
totally unfixed (n=14) or that were fixed with 0.5% glut 
araldehyde for 5 min (n=14). All sections were stained 
together on the same baths side-by-side. The mean O.D. 
units of the unfixed sections (10 readings/section) was 0.039 
(+0.002 standard deviation), while the mean for the fixed 
sections was 0.038 (+0.002 standard deviation). This differ 
ence (2.52%) was not statistically significant (p=0.30, 
t=1.07, df =13). It was determined that only a very small 
decrease in CO reactivity was produced by the brief fixation 
Step before the preincubation and incubation baths. This Step 
is done only to affix the Sections onto the Slides to prevent 
Sections from floating off during Subsequent Staining baths. 
The present CO cytochemical procedure demonstrated 
that it fulfills general quantitative methodological require 
ments detailed by Stoward (1980). First, there needs to be a 
way to Subtract any nonspecific Staining. This was done in 
the present method by image subtraction of the O.D. back 
ground of unreactive tissue Standards. Second, the change in 
O.D. must be linear during the incubation period (FIG. 10). 
Third, the enzyme activity must increase in proportion to 
tissue section thickness (FIG. 11). Finally, there needs to be 
a conversion procedure (FIG. 9) by comparison of data 
measured biochemically to provide a way to express mea 
Sures in O.D. as actual enzyme units. The validity of the 
conversion procedure was verified also using dissected brain 
regions. The method presented here fulfilled these quanti 
tative criteria and thus provides a Superior approach for 
regional mapping Studies of CO activity. 
All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of Skill in the art that variations may be 
applied to the compositions and methods and in the Steps or 
in the Sequence of Steps of the method described herein 
without departing from the concept, Spirit and Scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be Substituted for the agents described herein 
while the same or similar results would be achieved. All 
Such similar Substitutes and modifications apparent to those 
skilled in the art are deemed to be within the Spirit, Scope and 
concept of the invention as defined by the appended claims. 
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What is claimed is: 
1. A method of diagnosing late-onset sporadic Alzhe 
imer's Disease (AD) comprising the steps of: 
(a) obtaining a sample from a human Subject; 
(b) assessing cytochrome oxidase activity in nucleated 
cells of Said sample, and 
(c) comparing the cytochrome oxidase activity in nucle 
ated cells of Said Sample with the cytochrome oxidase 
activity of a Standard, 
wherein a decrease in cytochrome oxidase activity in nucle 
ated cells of Said Sample, with respect to Said Standard, 
indicates that Said Subject has AD. 
2. The method of claim 1, wherein said standard is 
cytochrome oxidase activity of nucleated cells of the same 
tissue type as the Sample from an individual not afflicted 
with AD. 
3. The method of claim 2, wherein said method further 
comprises assessing cytochrome oxidase activity from Said 
nucleated cells of the same tissue type as the Sample from an 
individual not afflicted with AD. 
4. The method of claim 1, wherein said sample is a 
Superficial tissue biopsy. 
5. The method of claim 4, wherein said biopsy is from a 
tissue Selected from the group consisting of muscle, dermis, 
epidermis, bone marrow, peripheral ganglion or nerve. 
6. The method of claim 1, wherein Said assessing com 
prises providing diaminobenzidine (DAB) to cells of said 










7. The method of claim 6, wherein measuring oxidation of 
DAB to an indamine polymer comprises quantitative 
cytochemistry when calibrated with Spectrophotometry. 
8. The method of claim 1, wherein said sample is frozen 
and Sectioned. 
9. The method of claim 1, wherein cytochrome oxidase 
activity is quantified. 
10. The method of claim 1, wherein the cytochrome 
oxidase activity level of cells of said sample is 15% or more 
below the cytochrome oxidase activity level of said nucle 
ated cells of the same tissue type as the Sample from an 
individual not afflicted with AD. 
11. A method for monitoring a treatment for late-onset 
Sporadic AD comprising the Steps of 
(a) obtaining a Sample from a human Subject following a 
treatment thereof; 
(b) assessing cytochrome oxidase activity in nucleated 
cells of Said Sample, and 
(c) comparing the cytochrome oxidase activity in nucle 
ated cells of Said Sample with a Standard; 
wherein an increase in cytochrome oxidase activity in nucle 
ated cells of Said Sample, with respect to Said Standard, 
indicates that Said treatment is effective. 
12. The method of claim 11, wherein said standard is 
cytochrome oxidase activity of nucleated cells of the same 
tissue type as the Sample from Said Subject prior to Said 
treatment. 
13. The method of claim 11, wherein said standard is 
cytochrome oxidase activity of Said nucleated cells of the 
Same tissue type as the Sample from an individual not 
afflicted with AD. 
14. The method of claim 11, wherein said sample is a 
Superficial tissue biopsy. 
15. The method of claim 11, wherein said assessing 
comprises providing diaminobenzidine (DAB) to cells of 
Said Sample and measuring oxidation of DAB to an 
indamine polymer. 
16. The method of claim 15, wherein measuring oxidation 
of DAB to an indamine polymer comprises quantitative 
cytochemistry when calibrated with Spectrophotometry. 
17. The method of claim 11, wherein said sample is frozen 
and Sectioned. 
18. A diagnostic kit comprising: 
(a) a cytochrome oxidase Substrate in a Suitable container 
means therefor; 
(b) a cytochrome oxidase enzyme preparation for use as 
a Standard, and a Suitable container means therefor. 
19. A kit of claim 18, wherein said Substrate is diami 
nobenzidine. 
20. A kit of claim 18, further comprising reagents for 
preparation of histological Samples. 
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